Compare Quest Diagnostics Inc (DGX) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Workiva Inc — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.24B), while Workiva Inc trades at $68.63 (market cap $3.70B). The key difference: Quest Diagnostics Inc is far larger — about 7.1× Workiva Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Workiva Inc pays none. Which is the better fit depends on your goals.
| DGX | WK | |
|---|---|---|
Market Cap | $26.24B | $3.70B |
Sector | Health | Technology |
52-Week High | $238.50 | $93.31 |
52-Week Low | $173.49 | $44.31 |
Enterprise Value | $32.00B | $3.68B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Workiva (WK) trades at $68.07, up 1.11% today, with strong technical momentum and bullish moving averages. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 revenue of $255 million exceeding guidance. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and a $69 consensus target. The stock shows robust revenue growth but elevated valuation multiples with a P/E of 82.2.
Outlook remains constructive given consistent earnings outperformance and strong subscription growth, though high valuation and negative net income in 2025 present risks. The company's AI platform expansion and Fortune 500 customer base support long-term growth potential, but investors should monitor profitability improvement and competitive pressures in the compliance software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
